Axa S.A. Kymera Therapeutics, Inc. Transaction History
Axa S.A.
- $32.2 Billion
- Q4 2024
A detailed history of Axa S.A. transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Axa S.A. holds 109,136 shares of KYMR stock, worth $3.23 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
109,136
Previous 109,312
0.16%
Holding current value
$3.23 Million
Previous $5.17 Million
15.14%
% of portfolio
0.01%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding KYMR
# of Institutions
187Shares Held
60.3MCall Options Held
49.6KPut Options Held
17K-
Price T Rowe Associates Inc Baltimore, MD6.87MShares$203 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$178 Million2.67% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$153 Million7.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.15MShares$153 Million3.02% of portfolio
-
Atlas Venture Life Science Advisors, LLC4.9MShares$145 Million32.49% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $1.62B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...